MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada

Table 4 Selected infant characteristics and outcomes according to exposure to MgSO4 for fetal NP and its indication (N (%) or median [IQR], where appropriate, unless otherwise indicated)

	MgSO4 for neuroprotection N = 5314	No MgSO4 N = 7238	MgSO4 for another indication N = 1556	p value
Antenatal and birth characteristics
GA, weeks and days	29 [26, 30]	29 [27, 30]	29 [27, 30]	< 0.001
24 weeks (and 0 days)–28 weeks (and 6 days)	2634 (49.6%)	3198 (44.2%)	682 (43.8%)	< 0.001
29 weeks (and 0 days)–31 weeks (and 6 days)	2680 (50.4%)	4040 (55.8%)	874 (56.2%)	< 0.001
Male	2908/5304 (54.8%)	3974/7233 (54.9%)	766 (49.9%)	< 0.001
Missing	10	5	3
Singleton	3644 (68.6%)	5095 (70.4%)	1189 (76.5%)	< 0.001
Missing	0	1	1
Small gestational age	545 (10.3%)	541 (7.5%)	277 (17.8%)	< 0.001
Missing	8	5	3
Maternal chorioamnionitis	995 (23.5%)	1046 (21.0%)	168 (15.0%)	< 0.001
Missing	1085	2264	439
Antenatal corticosteroids	5127 (96.9%)	5827 (81.7%)	1477 (95.8%)	< 0.001
Missing	23	108	14
Outborn	299 (5.6%)	1484 (20.5%)	128 (8.2%)	< 0.001
Missing	0	6	2
Delivered by caesarean	3082 (58.1%)	4260 (59.0%)	1119 (72.2%)	< 0.001
Missing	7	13	5
Intensive resuscitation	1630 (30.9%)	2828 (39.6%)	466 (30.3%)	< 0.001
Missing	33	91	19
Adjusted OR (vs no use)*	0.63 [0.54, 0.73]	Reference	–	< 0.001
Adjusted OR (vs other use)*	0.81 [0.66, 0.99]	–	Reference	0.04

*Adjusted for gestational age, gender, small for gestational age, singleton, outborn status, delivery by caesarean and administration of corticosteroids. Chorioamnionitis was not included due to a large proportion of missing variables

ISSN: 1748-5908